Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Quipt Home Medical Corp T.QIPT

Alternate Symbol(s):  QIPT

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators, continuous positive airway pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) units; traditional and non-traditional medical respiratory equipment and services, and non-invasive ventilation equipment, supplies, and services. The Company's product offerings include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. Its products and services consist of sleep apnea and pap treatment, home ventilation, daily and ambulatory aides, and respiratory equipment rental.


TSX:QIPT - Post by User

Comment by lscfaon May 19, 2022 9:59pm
134 Views
Post# 34697168

RE:Run-Rate $180M

RE:Run-Rate $180M

Justin Keywood

Okay. So a little higher than 135, but still below the reiterated guidance of $180 million to $190 million. So that implies that there's a lot of M&A opportunity in the back half of the year. How confident are you in executing on that M&A? And what are some of the factors that could defer some of those processes into the next year?

Hardik Mehta

Sure. So one thing to just make sure, I think we are accurate that the guidance that we have is what an annualized run rate would look like as we exit 2022 and end of 2023, right? And so yes, you're right, between now and the rest of the year, we do expect M&A and organic growth to get us to the annualized run rate that we have forecasted or given guidance on. We feel pretty confident that we would be able to get into that range. Our pipeline is pretty solid. We continue to enter into LOIs and execute on those. And there are no indications for us to believe that something will stall or we won't be able to get to that point as we stand today.

Greg Crawford

I think -- this is Greg. I think it's also worth noting in that historically in that if you go back and look over the last three-plus years, we've been very active on the M&A front in the back half of the year and expect to even be here in the near term.

 
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse